William G Wierda Selected Research

fludarabine

1/2022	The cure of leukemia through the optimist's prism.
12/2021	Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
11/2019	Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy.
1/2018	A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.
11/2017	A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
1/2017	Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy.
1/2016	Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.
1/2016	Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.
1/2016	Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity.
11/2015	Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

William G Wierda Research Topics

Disease

148	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022 - 06/2003
46	Neoplasms (Cancer) 01/2022 - 06/2003
24	Leukemia 01/2022 - 04/2004
16	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 06/2003
16	Disease Progression 12/2021 - 05/2005
11	Hematologic Neoplasms (Hematological Malignancy) 12/2021 - 04/2004
10	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2022 - 02/2003
9	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2022 - 02/2006
8	Lymphoma (Lymphomas) 02/2020 - 12/2003
7	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022 - 04/2006
7	Residual Neoplasm 12/2021 - 01/2011
7	Infections 01/2020 - 09/2003
7	Lymphadenopathy 11/2019 - 10/2007
6	Diarrhea 01/2021 - 02/2008
6	Lymphocytosis 01/2020 - 09/2011
6	B-Cell Lymphoma (Lymphoma, B Cell) 08/2019 - 06/2010
5	Tumor Lysis Syndrome 01/2022 - 01/2019
5	Philadelphia Chromosome 01/2022 - 02/2003
4	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2021 - 03/2017
4	Cytopenia 01/2021 - 09/2011
3	Exanthema (Rash) 01/2021 - 11/2017
3	Nausea 01/2020 - 02/2008
3	Trisomy (Trisomies) 07/2015 - 04/2008
2	Hairy Cell Leukemia 01/2022 - 06/2006
2	Acute Promyelocytic Leukemia 01/2022 - 11/2015
2	Hemorrhage 01/2021 - 12/2015
2	Thrombocytopenia (Thrombopenia) 01/2021 - 02/2008
2	Neutropenia 01/2021 - 01/2020
2	Headache (Headaches) 01/2021 - 01/2021
2	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2021 - 01/2021
2	Second Primary Neoplasms (Neoplasms, Second) 05/2019 - 07/2015
2	Fatigue 01/2018 - 02/2008

Drug/Important Bio-Agent (IBA)

34	ibrutinibIBA 01/2022 - 02/2012
29	fludarabineIBA 01/2022 - 06/2004
27	Rituximab (Mabthera)FDA Link 01/2022 - 04/2006
23	Agammaglobulinaemia Tyrosine KinaseIBA 01/2022 - 02/2012
22	venetoclaxIBA 01/2022 - 08/2015
15	Proteins (Proteins, Gene)FDA Link 01/2022 - 04/2004
14	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2021 - 04/2009
12	Lenalidomide (CC 5013)FDA Link 01/2019 - 06/2008
9	Tyrosine Kinase InhibitorsIBA 01/2022 - 12/2007
9	acalabrutinibIBA 01/2022 - 01/2016
9	Phosphotransferases (Kinase)IBA 01/2021 - 12/2007
9	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 08/2014 - 06/2003
8	ofatumumab FDA Link 01/2020 - 04/2010
8	Alemtuzumab (Campath)FDA Link 11/2011 - 12/2003
7	Monoclonal AntibodiesIBA 02/2020 - 12/2003
7	idelalisibIBA 11/2019 - 09/2011
6	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2022 - 01/2008
6	Biological ProductsIBA 11/2019 - 02/2006
6	Immunoglobulins (Immunoglobulin)IBA 04/2009 - 12/2003
5	Pharmaceutical PreparationsIBA 01/2022 - 02/2008
5	Biomarkers (Surrogate Marker)IBA 10/2021 - 09/2007
5	Imatinib Mesylate (Gleevec)FDA Link 09/2009 - 04/2004
4	obinutuzumabIBA 01/2022 - 07/2015
4	Chimeric Antigen ReceptorsIBA 01/2021 - 01/2015
4	Histone Deacetylase InhibitorsIBA 12/2017 - 11/2006
3	Apoptosis Regulatory ProteinsIBA 01/2022 - 05/2005
3	NucleotidesIBA 01/2022 - 02/2012
3	Dasatinib (BMS 354825)FDA Link 01/2022 - 12/2007
3	Chlorambucil (Leukeran)FDA Link 01/2022 - 07/2015
3	NucleosidesIBA 01/2022 - 09/2005
3	Azacitidine (5 Azacytidine)FDA Link 01/2021 - 10/2007
3	Immunoglobulin Variable RegionIBA 01/2020 - 04/2009
3	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2020 - 07/2015
3	Alkylating AgentsIBA 03/2017 - 04/2009
3	MicroRNAs (MicroRNA)IBA 06/2015 - 06/2013
3	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2013 - 05/2009
3	Messenger RNA (mRNA)IBA 04/2011 - 06/2005
2	blinatumomabIBA 01/2022 - 01/2022
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2022 - 05/2009
2	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2022 - 10/2007
2	vecabrutinibIBA 01/2022 - 01/2022
2	Core Binding Factors (Core-Binding Factor)IBA 01/2022 - 11/2015
2	pirtobrutinibIBA 01/2022 - 01/2021
2	tapotoclaxIBA 01/2022 - 01/2020
2	Cladribine FDA LinkGeneric 01/2022 - 06/2006
2	Adenosine Triphosphate (ATP)IBA 01/2022 - 06/2005
2	ponatinibIBA 01/2022 - 01/2021
2	Indicators and Reagents (Reagents)IBA 11/2021 - 06/2003
2	Decitabine FDA Link 01/2021 - 11/2006
2	ublituximabIBA 11/2019 - 02/2019
2	umbralisibIBA 11/2019 - 02/2019
2	Purine NucleosidesIBA 01/2018 - 11/2017
2	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 01/2018 - 11/2017
2	Clofarabine (Clolar)FDA Link 01/2018 - 11/2017
2	Transaminases (Aminotransferases)IBA 11/2017 - 12/2015
2	Bendamustine Hydrochloride FDA Link 03/2017 - 06/2014
2	carfilzomibIBA 09/2016 - 01/2015
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 06/2015 - 07/2008
2	Proteasome InhibitorsIBA 01/2015 - 04/2009
2	LigandsIBA 02/2014 - 11/2007
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 10/2013 - 01/2008

Therapy/Procedure

64	Therapeutics 01/2022 - 02/2003
10	Drug Therapy (Chemotherapy) 01/2022 - 12/2003
5	Salvage Therapy 01/2021 - 10/2007
4	Immunotherapy 07/2021 - 04/2010
4	Aftercare (After-Treatment) 01/2019 - 02/2003
2	Transplantation 01/2021 - 05/2015
2	Stem Cell Transplantation 05/2017 - 05/2015